Rational use of the EAC real-time quantitative PCR protocol in chronic myelogenous leukemia: report of three false-negative cases at diagnosis This letter is addressed to the paper by Gabert et al., 1 in which the Europe Against Cancer (EAC) program has proposed a standardized real-time quantitative polymerase chain reaction (RQ-PCR) protocol designed for studies of minimal residual disease (MRD) in fusion transcript bearing leukemia. Although this protocol has been established in the frame of molecular follow-up, its very practical use would prompt molecular labs to choose it as tool for diagnostic purposes, at least for BCR-ABL screening in chronic myelogenous leukemia (CML). This is an inappropriate approach as false-negative results at diagnosis of a CML may be encountered with the use of this protocol. Indeed, we report hereby three Philadelphia (Ph þ ) CML patients with a major breakpoint cluster region (M-bcr) rearrangement detectable by fluorescent in situ hybridization (FISH) and classical qualitative RT-PCR but not by RQ-PCR with the use of the standardized EAC protocol.
All three patients had clinical and biological features highly suggestive for CML. Bone marrow examination of the third patient also revealed 30% blasts with myeloid antigens. Cytogenetic analyses performed on bone marrow samples from patients 1 and 2 disclosed a 46,XX,t(9;22)(q34;q11) karyotype in 23 mitoses and a 46,XY,t(9;22)(q34;q11) karyotype in 30 mito- , and revealed, in all three cases, the typical profile in keeping with a BCR-ABL rearrangement targeting the major breakpoint region (see Figure 1 ).
In order to get a reference value for molecular follow-up, the pretherapeutic level of BCR-ABL transcripts was quantified by RQ-PCR approach performed on a 7700ABI platform (Applied Biosystems, Foster City, CA, USA). We used the standardized protocol and M-bcr set of primers and probe published by the EAC, 1 and designed to amplify both e13a2 (b2a2) and e14a2 (b3a2) fusion transcripts. No BCR-ABL fusion gene transcript was detected in all three cases. An additional qualitative RT-PCR assay was then performed for all cases, using a forward primer BCR exon 13 (5 0 AGATGCTGACCAACTCGTGTGTGA3 0 ) located 44 nucleotides upstream from the breakpoint fusion and a reverse primer located in ABL exon 3 (5 0 TGTGA TTATAGCCTAAGACCCGGAG3 0 ). Two hundred micromolar dNTP, 2.5 U of Taq polymerase and 1.6 mM of each primer were added to the PCR buffer (Invitrogen, Carlsbad, CA, USA). Polymerase chain reaction conditions were: 931C, 2 min 30 s, followed by 40 cycles of 931C, 1 min; 651C, 2 min; 721C, 3 min and a final elongation at 721C for 10 min. Sequence analysis of the PCR products obtained for all three cases demonstrated the presence of e13a2-type junctions and revealed a deletion of the 3 0 part of the BCR exon 13 sequence, located at the border of the breakpoint fusion and corresponding to the EAC forward primer hybridization site (see Figure 2' ). In patient 1, there was also a single-nucleotide insertion. For the two other cases, the deleted sequence was longer and partially replaced by the insertion of a sequence separating the e13a2-type junction and measuring 28 bp in length in patient 2 and 17 bp in patient 3 (see Figure 2) . According to the Gene Data Bank SNPper (http//bio.chip.org/ biotools), the inserted sequences in both cases correspond to a part of ABL intron 1b.
We are thus reporting three Ph þ CML cases with M-BCR-ABL rearrangement detectable by FISH and qualitative RT-PCR, but not by RQ-PCR (Taqman technology) using the EAC set of primers and probe targeting both e13a2 and e14a2 fusion transcripts. The possibility of an e19a2 BCR-ABL junction (p230 Bcr-Abl ) or rare atypical BCR-ABL transcripts involving various BCR exons 2, 3 was ruled out by qualitative PCR and sequencing. Also, the FISH profile observed (1F1R1G and one extra signal) was not in keeping with an e1a2 junction, which leads to the production of p190
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Bcr-Abl and occurs very rarely in CML. 2 In our three cases, the t(9;22) generated classical e13a2 transcripts, but the failure to identify any BCR-ABL transcript by RQ-PCR was owing to sequence rearrangements targeting the forward BCR primer hybridization site located at the border of the BCR-ABL junction.
Our examples are rare as they represent three cases among roughly 250 CML patients tested as we work with the EAC RQ-PCR protocol. Nevertheless, they demonstrate that this approach is not appropriate for diagnostic purposes in CML, and should not replace more reliable molecular methods such as FISH or the multiplex RT-PCR previously proposed by Cross et al. 4 Also, these false-negative cases illustrate the limits of the TaqMan methodology, which imposes a set of primers hybridizing very close to the fusion transcript junction in order to generate PCR products no more than 150 bp of size 5 as well as to target both e13a2 and e14a2 fusion transcripts in a single PCR. 1 It is thus very sensitive to the integrity of the junction sequence unlike other quantitative devices such as the LightCycler technology 6 as well as the previous competitive RT-PCR, which allow the use of protocols with primers and probes located at distance from the breakpoint junctions. Nevertheless, the EAC RQ-PCR program is becoming a standard practice as it provides great technical facilities and enables robust and reproducible interlaboratory results. It is thus highly probable that cases as described here are and will be more and more encountered in routine molecular laboratories dealing with diagnosis and follow-up in hematologic malignancies.
In conclusion, the EAC RQ-PCR protocol has not been designed for screening of fusion transcripts in leukemia, at least for the search of BCR-ABL fusion transcripts in CML. Other methods such as FISH or multiplex RT-PCR 4 should be the diagnostic tools proposed whenever a CML is suspected. Pretherapeutic level of BCR-ABL transcripts could be then, in a second step, determined by RQ-PCR reactions in order to get a reference value for an appropriate follow-up. Quantitative multivariate analysis from panels of marker proteins has demonstrated that marker protein expression profiles can distinguish specific ALL subtypes.
1,2 Here, we consider the application of immunophenotyping by flow cytometry (FC) to analyze AML samples using panels of antibodies to characterize specific blast cell populations. We test the applicability of unsupervised cluster analysis of immunophenotypic data in finding potential cryptic relations among AML patients. A total of 96 de novo pediatric AML patients (59 males; 37 females; median age 11, range 1-18 years) were investigated using multiparametric FC and analyzed by clustering methods normally applied in high-throughput gene expression profiling to identify new homogeneous subgroups with clinical relevance. In all cases, AML diagnosis was performed by golden standard protocols for morphology, cytochemistry, cytogenetics, immunophenotype and molecular biology.
